Sino Historical Cash Flow
| 688108 Stock | 11.00 0.21 1.87% |
Analysis of Sino Medical cash flow over time is an excellent tool to project Sino Medical Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Dividends Paid of 1.9 M or Capital Expenditures of 116.8 M as it is a great indicator of Sino Medical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Sino Medical Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sino Medical Sciences is a good buy for the upcoming year.
Sino |
About Sino Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Sino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sino's non-liquid assets can be easily converted into cash.
Sino Medical Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Sino Medical Sciences financial statement analysis. It represents the amount of money remaining after all of Sino Medical Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Sino Medical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sino Medical Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sino Medical Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Sino Medical's Capital Expenditures is projected to increase significantly based on the last few years of reporting. The current year's End Period Cash Flow is expected to grow to about 328.5 M, whereas Change To Inventory is forecasted to decline to (15.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Dividends Paid | 29.4K | 940.1K | 2.0M | 1.9M | Depreciation | 65.4M | 63.2M | 62.8M | 42.8M |
Sino Medical cash flow statement Correlations
Click cells to compare fundamentals
Sino Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sino Medical cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (13.9M) | 3.6M | (27.8M) | (18.4M) | (14.5M) | (15.3M) | |
| Change In Cash | 263.4M | (93.7M) | (256.9M) | (84.3M) | (14.8M) | (14.0M) | |
| Total Cashflows From Investing Activities | (178.1M) | (120.2M) | (186.6M) | (88.9M) | (80.0M) | (84.0M) | |
| Depreciation | 28.1M | 38.3M | 65.4M | 63.2M | 62.8M | 42.8M | |
| Capital Expenditures | 180.0M | 112.8M | 158.4M | 110.8M | 67.7M | 116.8M | |
| Total Cash From Operating Activities | 137.6M | 70.5M | (60.1M) | (111.3M) | 56.8M | 30.4M | |
| Net Income | 90.0M | 22.5M | (130.8M) | (162.4M) | (39.6M) | (37.6M) | |
| End Period Cash Flow | 638.4M | 544.7M | 287.8M | 203.4M | 188.6M | 328.5M | |
| Other Cashflows From Investing Activities | 1.9M | 6.3M | 2.0M | 621.0K | 714.2K | 678.5K | |
| Change To Netincome | (350.7K) | (3.8M) | 11.8M | 25.4M | 29.2M | 30.6M | |
| Change To Liabilities | 21.3M | 15.7M | (93.9M) | (40.0M) | (36.0M) | (34.2M) | |
| Free Cash Flow | (42.4M) | (42.3M) | (218.6M) | (222.1M) | (10.8M) | (11.4M) | |
| Change In Working Capital | 7.1M | 5.2M | (21.5M) | (50.6M) | (8.7M) | (9.1M) | |
| Begin Period Cash Flow | 375.0M | 638.4M | 544.7M | 287.8M | 203.4M | 345.8M | |
| Other Non Cash Items | 7.0M | 8.7M | 18.3M | 27.3M | 29.1M | 16.0M | |
| Change To Account Receivables | 6.0M | (13.7M) | 100.1M | 7.7M | 8.9M | 14.8M | |
| Total Cash From Financing Activities | 304.4M | (43.1M) | (9.4M) | 116.9M | 105.2M | 94.1M |
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Stock
The Cash Flow Statement is a financial statement that shows how changes in Sino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sino's non-liquid assets can be easily converted into cash.